Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) von Drilon, Alexander, Siena, Salvatore, Ou, Sai-Hong Ignatius, Patel, Manish, Ahn, Myung Ju, Lee, Jeeyun, Bauer, Todd M, Farago, Anna F, Wheler, Jennifer J, Liu, Stephen V, Doebele, Robert, Giannetta, Laura, Cerea, Giulio, Marrapese, Giovanna, Schirru, Michele, Amatu, Alessio, Bencardino, Katia, Palmeri, Laura, Sartore-Bianchi, Andrea, Vanzulli, Angelo, Cresta, Sara, Damian, Silvia, Duca, Matteo, Ardini, Elena, Li, Gang, Christiansen, Jason, Kowalski, Karey, Johnson, Ann D, Patel, Rupal, Luo, David, Chow-Maneval, Edna, Hornby, Zachary, Multani, Pratik S, Shaw, Alice T, De Braud, Filippo G

Volltext

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105 von Drilon, Alexander, Fu, Siqing, Patel, Manish R, Fakih, Marwan, Wang, Ding, Olszanski, Anthony J, Morgensztern, Daniel, Liu, Stephen V, Cho, Byoung Chul, Bazhenova, Lyudmila, Rodriguez, Cristina P, Doebele, Robert C, Wozniak, Antoinette, Reckamp, Karen L, Seery, Tara, Nikolinakos, Petros, Hu, Zheyi, Oliver, Jennifer W, Trone, Denise, McArthur, Katherine, Patel, Rupal, Multani, Pratik S, Ahn, Myung-Ju

Volltext

Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma von WITZIG, Thomas E, FLINN, Ian W, WHITE, Christine A, GORDON, Leo I, EMMANOUILIDES, Christos, CZUCZMAN, Myron S, SALEH, Mansoor N, CRIPE, Larry, WISEMAN, Gregory, OLEJNIK, Teresa, MULTANI, Pratik S

Volltext

Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin’s Lymphoma von WITZIG, Thomas E, WHITE, Christine A, GORDON, Leo I, WISEMAN, Gregory A, EMMANOUILIDES, Christos, MURRAY, James L, LISTER, John, MULTANI, Pratik S

Volltext

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer von Farago, Anna F., Le, Long P., Zheng, Zongli, Muzikansky, Alona, Drilon, Alexander, Patel, Manish, Bauer, Todd M., Liu, Stephen V., Ou, Sai-Hong I., Jackman, David, Costa, Daniel B., Multani, Pratik S., Li, Gary G., Hornby, Zachary, Chow-Maneval, Edna, Luo, David, Lim, Jonathan E., Iafrate, Anthony J., Shaw, Alice T.

Volltext

ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors von Chen, Christopher T, Khanna, Vishesh, Kummar, Shivaani, Abdul-Karim, Raghad M, Sommerhalder, David, Tolcher, Anthony W, Ueno, Naoto T, Davis, Sarah Lindsey, Orr, Douglas W, Hamilton, Erika, Patel, Manish R, Spira, Alexander I, Jauhari, Shekeab, Florou, Vaia, Duff, Maureen, Xu, Rongda, Wang, Jian, Barkund, Shravani R, Zhou, Haiying, Pankov, Aleksandr, Kong, Wayne, Jahchan, Nadine S, Jackson, Erica L, Sun, Jessica D, Junttila, Melissa R, Multani, Pratik S, Daemen, Anneleen, Chow Maneval, Edna, Munster, Pamela N

Volltext

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial von Wiseman, Gregory A., Gordon, Leo I., Multani, Pratik S., Witzig, Thomas E., Spies, Stewart, Bartlett, Nancy L., Schilder, Russell J., Murray, James L., Saleh, Mansoor, Allen, Roberta S., Grillo-López, Antonio J., White, Christine A.

Volltext

Neutropenia in Patients Treated with Rituximab von Voog, Eric, Morschhauser, Franck, Solal-Céligny, Philippe

Volltext

Interstitial Pneumonitis Related to Rituximab Therapy von Burton, Catherine, Kaczmarski, Richard, Jan-Mohamed, Riaz

Volltext

A phase I trial of continuous infusion of the multidrug resistance inhibitor zosuquidar with daunorubicin and cytarabine in acute myeloid leukemia von Lancet, Jeffrey E, Baer, Maria R, Duran, George E, List, Alan F, Fielding, Robert, Marcelletti, John F, Multani, Pratik S, Sikic, Branimir I

Volltext

Leukemic blast and natural killer cell P-glycoprotein function and inhibition in a clinical trial of zosuquidar infusion in acute myeloid leukemia von Marcelletti, John F, Multani, Pratik S, Lancet, Jeffrey E, Baer, Maria R, Sikic, Branimir I

Volltext

Preliminary Results of the Oral CD73 Inhibitor, Oric-533, in Relapsed/Refractory Multiple Myeloma (RRMM) von Rodriguez, Cesar, Solomon, Scott R., Paul, Barry, Nadeem, Omar, Patel, Meenal, Wang, Jian, Xu, Rongda, Junttila, Melissa, Daemen, Anneleen, Katewa, Subhash, Multani, Pratik S, Gonsalves, Wilson I.

Volltext

An open-label phase Ib study of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide von Shore, Neal D., Efstathiou, Eleni, Patel, Rupal, Xu, Rongda, Johnson, Ann, Multani, Pratik S., Morris, Michael J., Abida, Wassim

Volltext

Abstract P015: Biomarker results supporting selection of RP2D from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients... von Daemen, Anneleen, Barkund, Shravani, Johnson, Ann, Pankov, Aleksandr, Wang, Amber W., Zhou, Haiying, Multani, Pratik S., Maneval, Edna Chow, Friedman, Lori S., Patel, Rupal

Volltext

CD73 Inhibition Reverses Immunosuppression and Has Potential As an Immunomodulatory Therapy in Patients with Multiple Myeloma von Junttila, Melissa R, Ray, Arghya, Warne, Robert, Chen, Xi R, Du, Ting, Lui, Fang, Katewa, Subhash, Blank, Brian, Moore, Jared, Ndubaku, Chudi, Colas, Christophe, Multani, Pratik S, Nadeem, Omar, Chauhan, Dharminder, Anderson, Kenneth C., Friedman, Lori

Volltext

Biomarker results supporting selection of RP2D from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced... von Daemen, Anneleen, Pankov, Aleksandr, Barkund, Shravani, Zhou, Haiying, Duff, Maureen, Johnson, Ann, Xu, Rongda, Multani, Pratik S., Chow Maneval, Edna, Friedman, Lori

Volltext

Abstract P041: Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer von Abida, Wassim, Agarwal, Neeraj, Hahn, Andrew W., Shore, Neal, Sieber, Paul, Dorff, Tanya, Rettig, Mathew, Smith, Mathew, Monk, Paul, Xu, Rongda, Johnson, Ann, Daemen, Anneleen, Maneval, Edna Chow, Multani, Pratik S., Patel, Rupal, Morris, Michael J.

Volltext

Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors von Abdul-Karim, Raghad Muhsin, Tolcher, Anthony W., Kummar, Shivaani, Patel, Manish R., Spira, Alexander I., Jauhari, Shekeab, Duff, Maureen, Xu, Rongda, Johnson, Ann, Daemen, Anneleen, Multani, Pratik S., Chow Maneval, Edna, Munster, Pamela N.

Volltext

No clinical evidence for CD4+ cell depletion caused by rituximab von Saville, M. Wayne, Benyunes, Mark C., Multani, Pratik S.

Volltext

Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions von Pishvaian, Michael J., Rolfo, Christian Diego, Liu, Stephen V., Multani, Pratik S., Chow Maneval, Edna, Garrido-Laguna, Ignacio

Volltext